New EU states' fears over data protection

21 September 2003

The health ministers of 10 states due to join the European Union next year have adopted a declaration opposing new EU rules increasing data protection for medicines.

While the current Italian Presidency of the EU has said it is determined to make as much progress as possible on the review of pharmaceutical legislation (Review 2001), aiming for final adoption before enlargement in May 2004, the new states' health ministers say they have been "marginalized" in this process.

Their declaration, which was issued during an informal meeting of EU health ministers in Milan, Italy, this month, notes the "lengthy and difficult" accession negotiations preceding the adoption of current EU drug legislation, which Review 2001 aims to amend. The ministers highlight in particular the extension of the data exclusivity period up to 10 years from the current for six years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight